Disease duration and Medsger's severity score are associated with significant liver fibrosis in patients with systemic sclerosis

Sang Won Lee, Beom Kyung Kim, Junyong Park, doyoung kim, SangHoon Ahn, Jason Jungsik Song, YongBeom Park, Soo Kon Lee, KwangHyub Han, Seungup Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective. We investigated the prevalence and predictors of significant liver fibrosis in patients with systemic sclerosis (SSc) who had no evidences of liver diseases due to viral infection, drug, and heavy alcohol consumption. Methods. A total of 44 SSc patients were recruited. In addition to the clinical and laboratory data, the 2013 College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria score, modified Rodnan skin score (mRSS), and Medsger's severity score (MSS) were analysed. Liver stiffness (LS) was measured using transient elastography to assess the degree of liver fibrosis and 7.4 kPa was adopted as the cut-off value for significant liver fibrosis. Results. The median age of patients (38 women) was 54 years and the median disease duration was 41.0 months. The median LS value was 4.6 kPa. The median mRSS and MSS were 7.0 and 5.0, respectively. Six (13.6%) patients had significant liver fibrosis. Disease duration (standardised β=0.375, p=0.018) and MSS (standardised β=0.398, p=0.047) significantly correlated with LS values. In multivariate analysis, disease duration ≥63 months (odds ratio (OR) 19.166, 95% confidence interval 1.090, 336.962, p=0.043) and MSS ≥7 (OR 19.796, 95% confidence interval 1.439, 272.252, p=0.026) independently predicted the presence of significant liver fibrosis. Conclusion. The prevalence of significant liver fibrosis was relatively high (13.6%) and its independent predictors were disease duration and MSS.

Original languageEnglish
Pages (from-to)68-74
Number of pages7
JournalClinical and Experimental Rheumatology
Volume33
Publication statusPublished - 2015 Jan 1

Fingerprint

Systemic Scleroderma
Liver Cirrhosis
Liver
Odds Ratio
Confidence Intervals
Elasticity Imaging Techniques
Skin
Rheumatology
Virus Diseases
Alcohol Drinking
Liver Diseases
Multivariate Analysis
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

@article{87f36b738d2f469f8769106fb962a531,
title = "Disease duration and Medsger's severity score are associated with significant liver fibrosis in patients with systemic sclerosis",
abstract = "Objective. We investigated the prevalence and predictors of significant liver fibrosis in patients with systemic sclerosis (SSc) who had no evidences of liver diseases due to viral infection, drug, and heavy alcohol consumption. Methods. A total of 44 SSc patients were recruited. In addition to the clinical and laboratory data, the 2013 College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria score, modified Rodnan skin score (mRSS), and Medsger's severity score (MSS) were analysed. Liver stiffness (LS) was measured using transient elastography to assess the degree of liver fibrosis and 7.4 kPa was adopted as the cut-off value for significant liver fibrosis. Results. The median age of patients (38 women) was 54 years and the median disease duration was 41.0 months. The median LS value was 4.6 kPa. The median mRSS and MSS were 7.0 and 5.0, respectively. Six (13.6{\%}) patients had significant liver fibrosis. Disease duration (standardised β=0.375, p=0.018) and MSS (standardised β=0.398, p=0.047) significantly correlated with LS values. In multivariate analysis, disease duration ≥63 months (odds ratio (OR) 19.166, 95{\%} confidence interval 1.090, 336.962, p=0.043) and MSS ≥7 (OR 19.796, 95{\%} confidence interval 1.439, 272.252, p=0.026) independently predicted the presence of significant liver fibrosis. Conclusion. The prevalence of significant liver fibrosis was relatively high (13.6{\%}) and its independent predictors were disease duration and MSS.",
author = "Lee, {Sang Won} and Kim, {Beom Kyung} and Junyong Park and doyoung kim and SangHoon Ahn and Song, {Jason Jungsik} and YongBeom Park and Lee, {Soo Kon} and KwangHyub Han and Seungup Kim",
year = "2015",
month = "1",
day = "1",
language = "English",
volume = "33",
pages = "68--74",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",

}

TY - JOUR

T1 - Disease duration and Medsger's severity score are associated with significant liver fibrosis in patients with systemic sclerosis

AU - Lee, Sang Won

AU - Kim, Beom Kyung

AU - Park, Junyong

AU - kim, doyoung

AU - Ahn, SangHoon

AU - Song, Jason Jungsik

AU - Park, YongBeom

AU - Lee, Soo Kon

AU - Han, KwangHyub

AU - Kim, Seungup

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective. We investigated the prevalence and predictors of significant liver fibrosis in patients with systemic sclerosis (SSc) who had no evidences of liver diseases due to viral infection, drug, and heavy alcohol consumption. Methods. A total of 44 SSc patients were recruited. In addition to the clinical and laboratory data, the 2013 College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria score, modified Rodnan skin score (mRSS), and Medsger's severity score (MSS) were analysed. Liver stiffness (LS) was measured using transient elastography to assess the degree of liver fibrosis and 7.4 kPa was adopted as the cut-off value for significant liver fibrosis. Results. The median age of patients (38 women) was 54 years and the median disease duration was 41.0 months. The median LS value was 4.6 kPa. The median mRSS and MSS were 7.0 and 5.0, respectively. Six (13.6%) patients had significant liver fibrosis. Disease duration (standardised β=0.375, p=0.018) and MSS (standardised β=0.398, p=0.047) significantly correlated with LS values. In multivariate analysis, disease duration ≥63 months (odds ratio (OR) 19.166, 95% confidence interval 1.090, 336.962, p=0.043) and MSS ≥7 (OR 19.796, 95% confidence interval 1.439, 272.252, p=0.026) independently predicted the presence of significant liver fibrosis. Conclusion. The prevalence of significant liver fibrosis was relatively high (13.6%) and its independent predictors were disease duration and MSS.

AB - Objective. We investigated the prevalence and predictors of significant liver fibrosis in patients with systemic sclerosis (SSc) who had no evidences of liver diseases due to viral infection, drug, and heavy alcohol consumption. Methods. A total of 44 SSc patients were recruited. In addition to the clinical and laboratory data, the 2013 College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria score, modified Rodnan skin score (mRSS), and Medsger's severity score (MSS) were analysed. Liver stiffness (LS) was measured using transient elastography to assess the degree of liver fibrosis and 7.4 kPa was adopted as the cut-off value for significant liver fibrosis. Results. The median age of patients (38 women) was 54 years and the median disease duration was 41.0 months. The median LS value was 4.6 kPa. The median mRSS and MSS were 7.0 and 5.0, respectively. Six (13.6%) patients had significant liver fibrosis. Disease duration (standardised β=0.375, p=0.018) and MSS (standardised β=0.398, p=0.047) significantly correlated with LS values. In multivariate analysis, disease duration ≥63 months (odds ratio (OR) 19.166, 95% confidence interval 1.090, 336.962, p=0.043) and MSS ≥7 (OR 19.796, 95% confidence interval 1.439, 272.252, p=0.026) independently predicted the presence of significant liver fibrosis. Conclusion. The prevalence of significant liver fibrosis was relatively high (13.6%) and its independent predictors were disease duration and MSS.

UR - http://www.scopus.com/inward/record.url?scp=84946234202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946234202&partnerID=8YFLogxK

M3 - Article

C2 - 26243041

AN - SCOPUS:84946234202

VL - 33

SP - 68

EP - 74

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

ER -